3637-technical-bulletin-mtd-isa-760-vg4536718630311562122

1
SEPPIC SA SEPPIC Inc SEPPIC UK Ltd SEPPIC Italia Srl 33(0) 1 42 91 40 00 1 973 882 5597 www.seppic.com 44 208 577 8800 39 02 38009110 Givaudan-Lavirotte SA SEPPIC China SEPPIC GmbH SEPPIC Belgium NV 33(0) 4 78 61 55 00 86(21) 64 66 01 49 Subsidiary of the AIR LIQUIDE group 49(0) 220 3890 3100 32 3 250 3911 3637/GB/01/August 07 Animal species: Technical Bulletin MONTANIDE TM ISA 760 VG Ready to use adjuvant for veterinary vaccines MONTANIDE TM ISA 760 VG is based on synthetic lipophilic polymer and biodegradable ester mix with an extremely refined emulsifier obtained from mannitol and purified oleic acid of vegetable origin. It has been developed for the manufacture of water-in-polymer emulsions. MONTANIDE TM ISA 760 VG is free of animal origin ingredients. Vaccine formulations with MONTANIDE TM ISA 760 VG induce a strong and long term immunity. Compared to traditional oil emulsions, MONTANIDE TM ISA 760 VG emulsions are very stable, well tolerated and easy to inject. 1. VACCINE PREPARATION: To prepare 100 g of vaccine, a typical composition is recommended: MONTANIDEISA 760 VG: 70 g Aqueous antigenic medium: 30 g Stable preparations are obtained by mixing the aqueous medium into the MONTANIDE TM ISA 760 VG, at room temperature or less, under vigorous stirring. The use of a high shear mixer is necessary to prepare a stable and efficient vaccine. Adjuvant concentration can be adjusted at 60 % (W/W) to get more room for the antigenic media, while checking the stability and the injectability of the emulsion. 2. EMULSION CHARACTERISTICS: (on placebo antigenic medium) TYPICAL STABILITY TYPE VISCOSITY (mPa.s) CONDUCTIVITY (μS/cm) DROPLET SIZE (micron) After storage at 4°C After storage at 25°C After storage at 37°C W/P (water-in- polymer) About 40 at 25°C < 10 1 or less At least 12 months At least 6 months About 15 days 3. IMMUNE RESPONSE: MONTANIDE TM ISA 760 VG is capable of improving vaccine efficacy via the induction of a strong and long lasting immunity. It’s a promising adjuvant to stimulate humoral responses. This product is recommended for bacterial, mycoplasma, viral or parasite antigens. 4. ANIMAL SPECIES: MONTANIDEISA 760 VG adjuvant is recommended for different vaccines for cattle, swine, poultry and fish. 5. STRENGTH: This adjuvant is a flexible and robust formulation. It is adapted to prepare water-in-polymer emulsions, which induce a strong efficacy similar to oil emulsions. Furthermore it offers the possibility to reduce the injected dose or to dilute antigenic media with a constant injected volume while keeping the same level of protection. 6. SAFETY AND REGULATORY: The toxicological tests made on MONTANIDE TM ISA range (Berlin test, Oral LD 50, IP LD 50, ocular irritation test, dermal irritation test, pyrogenicity) conclude to the safety and favourable tolerance of these adjuvants. Montanideadjuvants and their components have been considered as safe by the Committee for Veterinary Medical Products (CVMP) for use in immunological products and are included as authorized substances in the annex of the European Council Regulation n° 470/2009 (previously 2377/90/EC) needing no further MRL studies, or included in already registered veterinary commercial products. The properties of the antigenic media are crucial for the vaccine efficacy but also for its safety. Each team developing a vaccine will have to study the safety and efficacy profile of the underdevelopment formula according to local market acceptance criteria. For more information on this product or for any advice regarding the optimization of your vaccine, please contact our teams on www.seppic.com or on [email protected] Hydrophobic phase made of lipophilic polymer and bio- degradable esters (Does not contain mineral oil) For stable, fluid, and well tolerated vaccines Induces a strong and long lasting immune response MONTANIDElisted on Annex II of the European Council Regulation 2377/90/EC Key Points :

Upload: thuthao-le

Post on 17-Sep-2015

2 views

Category:

Documents


0 download

DESCRIPTION

sinh

TRANSCRIPT

  • SEPPIC SA SEPPIC Inc SEPPIC UK Ltd SEPPIC Italia Srl

    33(0) 1 42 91 40 00 1 973 882 5597 www.seppic.com 44 208 577 8800 39 02 38009110Givaudan-Lavirotte SA SEPPIC China SEPPIC GmbH SEPPIC Belgium NV33(0) 4 78 61 55 00 86(21) 64 66 01 49 Subsidiary of the AIR LIQUIDE group 49(0) 220 3890 3100 32 3 250 3911

    36

    37

    /GB/0

    1/A

    ugust

    07

    Animal species:

    Technical Bulletin

    MONTANIDETM ISA 760 VGReady to use adjuvant for veterinary vaccines

    MONTANIDETM

    ISA 760 VG is based on synthetic lipophilic polymer andbiodegradable ester mix with an extremely refined emulsifier obtainedfrom mannitol and purified oleic acid of vegetable origin. It has beendeveloped for the manufacture of water-in-polymer emulsions.

    MONTANIDETM

    ISA 760 VG is free of animal origin ingredients.

    Vaccine formulations with MONTANIDETM

    ISA 760 VG induce a strong and long

    term immunity. Compared to traditional oil emulsions, MONTANIDETM

    ISA 760VG emulsions are very stable, well tolerated and easy to inject.

    1. VACCINE PREPARATION:To prepare 100 g of vaccine, a typical composition is recommended:

    MONTANIDE ISA 760 VG: 70 g Aqueous antigenic medium: 30 g

    Stable preparations are obtained by mixing the aqueous medium into the MONTANIDETM

    ISA 760 VG, at roomtemperature or less, under vigorous stirring. The use of a high shear mixer is necessary to prepare a stable and efficientvaccine. Adjuvant concentration can be adjusted at 60 % (W/W) to get more room for the antigenic media, while checkingthe stability and the injectability of the emulsion.

    2. EMULSION CHARACTERISTICS: (on placebo antigenic medium)

    TYPICAL STABILITYTYPE

    VISCOSITY(mPa.s)

    CONDUCTIVITY(S/cm)

    DROPLET SIZE(micron)

    After storage at4C

    After storage at25C

    After storage at37C

    W/P(water-in-polymer)

    About 40at 25C

    < 10 1 or less At least 12 months At least 6 months About 15 days

    3. IMMUNE RESPONSE: MONTANIDETM

    ISA 760 VG is capable of improving vaccine efficacy via the induction of a strongand long lasting immunity. Its a promising adjuvant to stimulate humoral responses. This product is recommendedfor bacterial, mycoplasma, viral or parasite antigens.

    4. ANIMAL SPECIES: MONTANIDE ISA 760 VG adjuvant is recommended for different vaccines for cattle, swine,poultry and fish.

    5. STRENGTH: This adjuvant is a flexible and robust formulation. It is adapted to prepare water-in-polymeremulsions, which induce a strong efficacy similar to oil emulsions. Furthermore it offers the possibility to reduce theinjected dose or to dilute antigenic media with a constant injected volume while keeping the same level of protection.

    6. SAFETY AND REGULATORY: The toxicological tests made on MONTANIDETM

    ISA range (Berlin test, Oral LD 50, IP LD 50,ocular irritation test, dermal irritation test, pyrogenicity) conclude to the safety and favourable tolerance of theseadjuvants.Montanide adjuvants and their components have been considered as safe by the Committee for Veterinary MedicalProducts (CVMP) for use in immunological products and are included as authorized substances in the annex of theEuropean Council Regulation n 470/2009 (previously 2377/90/EC) needing no further MRL studies, or included inalready registered veterinary commercial products.The properties of the antigenic media are crucial for the vaccine efficacy but also for its safety. Each team developing avaccine will have to study the safety and efficacy profile of the underdevelopment formula according to local marketacceptance criteria.

    For more information on this product or for any advice regarding the optimization of your vaccine,please contact our teams on www.seppic.com or on [email protected]

    Hydrophobic phase made oflipophilic polymer and bio-degradable esters(Does not contain mineral oil)

    For stable, fluid, and welltolerated vaccines

    Induces a strong and longlasting immune response

    MONTANIDE listed on AnnexII of the European CouncilRegulation 2377/90/EC

    Key Points :